L. A. Wozniak, M. Janicka, M. Bukowiecka-Matusiak
FULL PAPER
twice with dry benzene (5 mL) and CH2Cl2 (5 mL) and kept over-
night in a desiccator under high vacuum (r.t., 0.01 Torr), dissolved
in CH2Cl2 (dried with CaH2, and stored under argon with 4 Å
molecular sieves) (3 mL), and treated with diisopropylethylamine
(4.4 equiv.) and β-cyanoethyl N,N-diisopropylchlorophosphoram-
idite (2.2 equiv.) with vigorous stirring. The reaction progress was
monitored by TLC (HP TLC plate analysis; chloroform/MeOH,
9:1 v/v). When the reaction was complete, the reaction mixture was
loaded directly into a silica gel column equilibrated with an ethyl
acetate/CH2Cl2/MeCN (3:1:1 v/v) mixture containing 1% of Et3N.
The column was run under a positive pressure of argon using the
same eluent. Fractions containing product 4 were concentrated to
afford pure products 4 as colorless foams. These were dissolved in
dichloromethane and precipitated in cold hexane. White powders
were isolated after centrifugation, dried under vacuum, and stored
at –20 °C under argon. Yields: 80–82%. 31P NMR: (RP)-4 (CDCl3):
δ = 99.3, 99.1 [(RP)-methylphosphonothioate signals] and 149.5,
148.8 ppm (phosphoramidite signals). FAB MS: m/z = 1162.6 [M –
H]–, 1164.7 [M + H]+ (C55H71N7O15PS: calcd. 1163.42). 31P NMR:
(SP)-4 (CDCl3): δ = 97.4, 97.5 ppm (SP)-methylphosphonothioate
signals) and 151.67, 151.34 ppm (phosphoramidite signals). FAB
MS: m/z = 1164.7 [M – H]+ (C55H71N7O15PS: calcd. 1163.42).
band width, and 1–2 s integration time. Each spectrum was
smoothed with a 9- or 15-point algorithm (included in the manu-
facturer’s software, version 2.2.1) after averaging of at least three
scans.
Supporting Information: Synthesis, NMR and MS (MALDI-TOF)
data are available along with colour figures illustrating molecular
modelling results for hybrid duplexes (2f/RNA).
Acknowledgments
This work was financially assisted by the State Committee for Sci-
entific Research (KBN-Grant 4 TO9A 073 25 awarded to L. A.
W.). The authors are indebted to Prof. W. J. Stec for his interest in
this work and helpful discussions, Dr. S. Kazmierski for NMR
analysis, and T. Ke˛błowska for skillful technical assistance.
[1] C. A. Stein, A. M. Krieg (Eds.), Applied Antisense Oligonucleo-
tide Technology, Wiley-Liss, New York, 1998.
[2] M. Phillips (Ed.), “Antisense Technology” in Methods in Enzy-
mology, Academic Press, 1999, vol. 314, part B.
[3] Protocols in Nucleic Acids Chemistry (Eds.: S. L. Beaucage,
D. E. Bergstrom, G. D. Glick, R. A. Jones), John Wiley & Sons,
Inc., Hoboken, NJ, 2003, 4.17.1–4.17.25.
[4] B. H. Loyd, R. V. Giles, D. G. Spiller, J. Grzybowski, D. M.
Tidd, Nucleic Acids Res. 2001, 29, 3664–3673.
[5] S. T. Crooke, Annu. Rev. Med. 2004, 55, 61–95.
[6] E. Wickstrom (Ed.), Clinical Trials of Genetic Therapy with
Antisense DNA and DNA Vectors, Marcel Dekker, Inc., New
York, 1998.
[7] M. Warashina, B. Nawrot, S. Obika, L. A. Wozniak, T. Kuwab-
ara, T. Imanishi, W. J. Stec, K. Taira in Synthetic Nucleic Acids
as Inhibitors of Gene Expression: Mechanisms, Applications and
Therapeutic Implications (Ed.: L. M. Khachigian), CRC Press,
Boca Raton, FL, 2005, pp. 95–113.
[8] M. R. Kurpiewski, M. Koziołkiewicz, A. Wilk, W. J. Stec, L.
Jen-Jacobson, Biochemistry 1996, 35, 8846–8854.
[9] S. A. Smith, L. W. McLaughlin, Biochemistry 1997, 36, 6046–
6058.
[10] T. M. Okonogi, S. C. Alley, E. A. Harwood, P. B. Hopkins,
B. H. Robinson, Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 4156–
4160.
[11] P. R. Hardwidge, J. M. Zimmerman, L. J. Maher, Nucleic Acids
Res. 2002, 30, 1879–1885.
[12] K. F. Pirollo, A. Rait, L. S. Sleer, E. H. Chang, Pharmacol.
Ther. 2003, 99, 55–77.
[13] Y. S. Cho-Chung, C. A. Stein, A. M. Gewirtz (Eds.), “Thera-
peutic Oligonucleotides: Antisense, Rnai, Triple-Helix, Gene Re-
pair, Enhancer Decoys, Cpg, and DNA Chips” in Annals of the
New York Academy of Sciences, New York Academy of Sci-
ences, New York, 2004.
[14] M. A. Reynolds, R. I. Hogrefe, J. A. Jaeger, D. A. Schwartz,
T. A. Riley, W. B. Marvin, W. J. Daily, M. M. Vaghefi, T. A.
Beck, S. K. Knowles, R. E. Klem, L. J. Arnold Jr., Nucleic Ac-
ids Res. 1996, 24, 4584–4591.
[15] P. S. Miller, N. D. Annan, S. M. McParland, K. B. Pulford,
Biochemistry 1982, 21, 2507–2512.
[16] P. S. Miller, N. S. Dreon, M. Pulford, K. B. McParland, J. Biol.
Chem. 1980, 255, 9659–9665.
[17] M. Jaworska-Maslanka, W. Kacperczyk, D. Korczynski, Z. J.
Lesnikowski, Antisense Nucleic Acid Drug Dev. 1997, 7, 23–30.
[18] Z. J. Lesnikowski, M. Jaworska, W. J. Stec, Nucleic Acids Res.
1990, 18, 2109–2115.
[19] W. J. Stec, Z. Les´nikowski in Methods in Molecular Biology,
Protocols for Oligonucleotides and Analogs (Ed.: S. Agrawal),
Humana Press, Inc., Totowa, NJ, 1993.
[20] L. Tian, Ch. D. Claeboe, S. M. Hecht, S. Shuman, Structure
2004, 12, 31–40.
Solid-phase Synthesis of Chimeric Oligonucleotides 2 Using Dimeric
Building Block 4: Oligomers 2 and 8–13 were prepared on a 1 µmol
scale using an ABI 392 Synthesizer (Applied Biosystems Inc., Fos-
ter City, USA). Incorporation of the dimeric building blocks 4 re-
quired an increase in the coupling time to 180 s without any further
modifications of the protocol. Removal of the base-protecting
groups and cleavage from the solid support was achieved by treat-
ment of the CPG-bound oligomers with NH4OH/MeOH solution
(2:1 v/v) at room temperature for 8 h followed by HPLC purifica-
tion of oligomers (DMT-ON; ODS Hypersil column, Shandon,
UK, 210×4.6 mm, gradient 2–40% MeCN, 0.1 TEAB buffer,
pH 7.5). Standard removal of the 5Ј-DMT group was followed by
RP HPLC purification (ODS Hypersil C18, gradient 2–20%
MeCN, 0.1 TEAB buffer, pH 7.5). The purity of all oligomers
was confirmed by gel electrophoresis. Their structures were con-
firmed by MALDI-TOF spectrometry (see Table 1).
Melting Profiles and Thermodynamic Calculations: All absorption
measurements were carried out in a cell of 1 cm pathlength with a
UV/Vis 916 spectrophotometer equipped with a Peltier Thermocell
(GBC UV/Vis 916, GBC, Dandenong, Australia). The concentra-
tion of oligomers was determined spectrophotometrically by UV
absorbance at λmax in water using the extinction coefficients calcu-
lated by the published method.[48] The unmodified phosphodiester
oligonucleotides d(TC)5T (11) and r(UC)5U2Ј–OMe (12) as well as
chimeric oligonucleotides 2 were lyophilized and redissolved in
10 m Tris-HCl, 100 m NaCl, 10 m MgCl2 buffer (pH = 7.4)
and complementary templates were dissolved in the same buffer at
a total concentration of duplexes of 4 µ. Oligo-MePS 2, and the
appropriate templates were mixed together, heated at 90 °C for
5 min, and kept overnight at 4 °C. Melting profiles were recorded
between 3 and 95 °C in both directions with a temperature gradient
of 0.3 °C/min. The melting temperatures were calculated using the
first-order derivative method. Thermodynamic parameters were
obtained numerically by fitting an analytical curve resulting from
a two-state model to experimental melting profiles. The procedure
applied for fitting was a nonlinear least-squares method included
in the Sigma Plot software (version 5.01).
CD Spectra: CD spectra were recorded in the same buffer at a
concentration of 4 µ on
a CD6 dichrograph (Jobin–Yvon,
Longjumeau, France) using cells with a 5 mm pathlength, 2 nm
5196
www.eurjoc.org
© 2005 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Eur. J. Org. Chem. 2005, 5189–5197